Synthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cells

Handle URI:
http://hdl.handle.net/10754/627127
Title:
Synthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cells
Authors:
Hasan, Mohammed Nihal; Choudhry, Hani; Razvi, Syed Shoeb; Moselhy, Said Salama; Kumosani, Taha Abduallah; Zamzami, Mazin A.; Omran, Ziad; Halwani, Majed A. ( 0000-0002-2192-3264 ) ; Al-Babili, Salim ( 0000-0003-4823-2882 ) ; Abualnaja, Khalid Omer; Al-Malki, Abdulrahman Labeed; Alhosin, Mahmoud; Asami, Tadao
Abstract:
Hepatocellular carcinoma (HCC) remains one of the leading causes of death worldwide. The complex etiology is attributed to many factors like heredity, cirrhosis, hepatitis infections or the dysregulation of the different molecular pathways. Nevertheless, the current treatment regimens have either severe side effects or tumors gradually acquire resistance upon prolonged use. Thus, developing a new selective treatment for HCC is the need of the hour. Many anticancer agents derived from plants have been evaluated for their cytotoxicity towards many human cancer cell lines. Strigolactones (SLs)-a newly discovered class of phytohormones, play a crucial role in the development of plant-root and shoot. Recently, many synthetic analogues of SLs have demonstrated pro-apoptotic effects on different cancer cell lines like prostate, breast, colon and lung. In this study, we tested synthetic SLs analogues on HCC cell line-HepG2 and evaluated their capability to induce cell proliferation inhibition and apoptosis. Primary WST-1 assays, followed by annexin-V/7AAD staining, demonstrated the anti-proliferative effects. The SLs analogues TIT3 and TIT7 were found to significantly reduce HepG2 cell viability in a dose- and time-dependent manner and induce apoptosis. Interestingly, though TIT3 and TIT7 strongly affected cancer cell proliferation, both compounds showed moderate anti-proliferative effect on normal cells. Further, migration of cancer cells was suppressed upon treatment with TIT3 and TIT7 in a wound healing assay. In summary, these findings suggest that two SLs analogues TIT3 and TIT7 exert selective inhibitory effects on cancer cells most likely through targeting microtubules. SLs analogues could be used in future as potential anti-cancer candidates in chemotherapy.
KAUST Department:
Biological and Environmental Sciences and Engineering (BESE) Division; Plant Science Program; Desert Agriculture Initiative; Computational Bioscience Research Center (CBRC)
Citation:
Hasan MN, Choudhry H, Razvi SS, Moselhy SS, Kumosani TA, et al. (2018) Synthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cells. Bioorganic & Medicinal Chemistry Letters. Available: http://dx.doi.org/10.1016/j.bmcl.2018.02.016.
Publisher:
Elsevier BV
Journal:
Bioorganic & Medicinal Chemistry Letters
Issue Date:
9-Feb-2018
DOI:
10.1016/j.bmcl.2018.02.016
Type:
Article
ISSN:
0960-894X
Sponsors:
The authors appreciate the endeavours of DSR in supporting this project financially and technically. This study was funded by the Deanship of Scientific Research (DSR), at King Abdulaziz University, Jeddah, under grant no: HiCi-1-130- 36.
Additional Links:
http://www.sciencedirect.com/science/article/pii/S0960894X18301057
Appears in Collections:
Articles; Center for Desert Agriculture; Computational Bioscience Research Center (CBRC); Plant Science Program; Biological and Environmental Sciences and Engineering (BESE) Division

Full metadata record

DC FieldValue Language
dc.contributor.authorHasan, Mohammed Nihalen
dc.contributor.authorChoudhry, Hanien
dc.contributor.authorRazvi, Syed Shoeben
dc.contributor.authorMoselhy, Said Salamaen
dc.contributor.authorKumosani, Taha Abduallahen
dc.contributor.authorZamzami, Mazin A.en
dc.contributor.authorOmran, Ziaden
dc.contributor.authorHalwani, Majed A.en
dc.contributor.authorAl-Babili, Salimen
dc.contributor.authorAbualnaja, Khalid Omeren
dc.contributor.authorAl-Malki, Abdulrahman Labeeden
dc.contributor.authorAlhosin, Mahmouden
dc.contributor.authorAsami, Tadaoen
dc.date.accessioned2018-02-13T13:43:19Z-
dc.date.available2018-02-13T13:43:19Z-
dc.date.issued2018-02-09en
dc.identifier.citationHasan MN, Choudhry H, Razvi SS, Moselhy SS, Kumosani TA, et al. (2018) Synthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cells. Bioorganic & Medicinal Chemistry Letters. Available: http://dx.doi.org/10.1016/j.bmcl.2018.02.016.en
dc.identifier.issn0960-894Xen
dc.identifier.doi10.1016/j.bmcl.2018.02.016en
dc.identifier.urihttp://hdl.handle.net/10754/627127-
dc.description.abstractHepatocellular carcinoma (HCC) remains one of the leading causes of death worldwide. The complex etiology is attributed to many factors like heredity, cirrhosis, hepatitis infections or the dysregulation of the different molecular pathways. Nevertheless, the current treatment regimens have either severe side effects or tumors gradually acquire resistance upon prolonged use. Thus, developing a new selective treatment for HCC is the need of the hour. Many anticancer agents derived from plants have been evaluated for their cytotoxicity towards many human cancer cell lines. Strigolactones (SLs)-a newly discovered class of phytohormones, play a crucial role in the development of plant-root and shoot. Recently, many synthetic analogues of SLs have demonstrated pro-apoptotic effects on different cancer cell lines like prostate, breast, colon and lung. In this study, we tested synthetic SLs analogues on HCC cell line-HepG2 and evaluated their capability to induce cell proliferation inhibition and apoptosis. Primary WST-1 assays, followed by annexin-V/7AAD staining, demonstrated the anti-proliferative effects. The SLs analogues TIT3 and TIT7 were found to significantly reduce HepG2 cell viability in a dose- and time-dependent manner and induce apoptosis. Interestingly, though TIT3 and TIT7 strongly affected cancer cell proliferation, both compounds showed moderate anti-proliferative effect on normal cells. Further, migration of cancer cells was suppressed upon treatment with TIT3 and TIT7 in a wound healing assay. In summary, these findings suggest that two SLs analogues TIT3 and TIT7 exert selective inhibitory effects on cancer cells most likely through targeting microtubules. SLs analogues could be used in future as potential anti-cancer candidates in chemotherapy.en
dc.description.sponsorshipThe authors appreciate the endeavours of DSR in supporting this project financially and technically. This study was funded by the Deanship of Scientific Research (DSR), at King Abdulaziz University, Jeddah, under grant no: HiCi-1-130- 36.en
dc.publisherElsevier BVen
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S0960894X18301057en
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Bioorganic & Medicinal Chemistry Letters. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Bioorganic & Medicinal Chemistry Letters, [, , (2018-02-09)] DOI: 10.1016/j.bmcl.2018.02.016 . © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectStrigolactonesen
dc.subjectLiver canceren
dc.subjectApoptosisen
dc.subjectCell proliferationen
dc.subjectHepatocellular carcinomaen
dc.titleSynthetic Strigolactone Analogues Reveal Anti-Cancer Activities on Hepatocellular Carcinoma Cellsen
dc.typeArticleen
dc.contributor.departmentBiological and Environmental Sciences and Engineering (BESE) Divisionen
dc.contributor.departmentPlant Science Programen
dc.contributor.departmentDesert Agriculture Initiativeen
dc.contributor.departmentComputational Bioscience Research Center (CBRC)en
dc.identifier.journalBioorganic & Medicinal Chemistry Lettersen
dc.eprint.versionPost-printen
dc.contributor.institutionDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabiaen
dc.contributor.institutionBioactive Natural Products Research Group, King Abdulaziz University, Jeddah, Saudi Arabiaen
dc.contributor.institutionCancer and Mutagenesis Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabiaen
dc.contributor.institutionCancer Metabolism and Epigenetic Unit, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabiaen
dc.contributor.institutionBiochemistry Department, Faculty of Science, Ain shams University, Cairo, Egypten
dc.contributor.institutionExperimental Biochemistry Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabiaen
dc.contributor.institutionProduction of Bioproducts for Industrial Applications Research Group, King Abdulaziz University, Jeddah, Saudi Arabiaen
dc.contributor.institutionCollege of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabiaen
dc.contributor.institutionNanomedicine Department, King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences, Saudi Arabiaen
dc.contributor.institutionGraduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo, Tokyo 113–8657, Japanen
kaust.authorAl-Babili, Salimen
All Items in KAUST are protected by copyright, with all rights reserved, unless otherwise indicated.